myTomorrows has secured €25 million in growth equity to speed up access to emerging therapies for patients who have exhausted standard options. The round was led by Avego Healthcare Capital and closed in October 2025, positioning the company to scale its global platform. The funding underscores rising demand for solutions that connect patients and physicians to pre-approval treatments with greater speed, clarity, and compliance.
Background
Founded after a firsthand struggle to access investigational therapies, myTomorrows initially focused on distributing medicines through paid expanded access programs. In 2020, the company broadened its model to unify clinical trial access and expanded access pathways on a single platform. That shift transformed myTomorrows from a distribution partner into a global access solution combining technology and high-touch navigation.
Funding Details
Avego Healthcare Capital Fund II L.P. brings sector expertise across life sciences, clinical development, and patient access. With this investment, myTomorrows aims to address the structural barriers that keep patients from promising therapies, including fragmented systems and regulatory complexity. The capital marks a pivotal step as regulators and industry players increasingly seek earlier, evidence-driven access mechanisms.
Strategy and Use of Proceeds
Proceeds will expand the company’s global reach and deepen its role as a centralized hub for pre-approval treatments. myTomorrows will enhance its AI capabilities to accelerate patient matching and streamline compliant request initiation for trials and expanded access programs. The company will also strengthen BioPharma partnerships, grow real-world data generation, and scale patient support from education through follow-up.
Platform and Services
The platform brings trials and expanded access programs into one interface for patients, physicians, and sponsors. AI-powered matching can reduce pre-screening time by up to 90 percent, giving clinical teams faster visibility into eligibility. A multilingual navigation team provides personalized assistance across time zones to ensure each pathway is pursued efficiently and compliantly.
Current Footprint and Impact
Headquartered in Amsterdam with offices in New York and an operational hub in India, myTomorrows operates at international scale. The company reports more than 16,900 patients enrolled, support for over 2,800 physicians, and engagement with more than 340 clinical sites. Partnerships span upwards of 60 biopharma companies, complemented by ties to patient advocacy communities.
Market Context
Despite roughly 10,000 therapies in development or not yet approved, many patients still lack timely access to suitable options. The gap is exacerbated by disconnected information, varying regulations, and geographic disparities that complicate decision-making for clinicians and families. A unified, data-driven access model seeks to shorten timelines and improve equity without compromising compliance.
Outlook
myTomorrows aims to be the first destination for patients and physicians when standard treatments fail or when every possible avenue must be explored. The company plans to convert early access activity into robust real-world evidence that can inform regulatory submissions and development decisions. As healthcare becomes more data-centric and patient-focused, the platform intends to serve as a trusted, time-saving resource across stakeholders.
Leadership Perspective
Chief Executive Officer Michel van Harten, MD, brings clinical and industry experience shaped by years treating complex cancer cases. His leadership emphasizes combining intelligent digital tools with human guidance to navigate sensitive, time-critical choices. The new capital validates that approach and supports a push toward broader, faster, and more transparent access.
The €25 million growth round led by Avego positions myTomorrows to accelerate its mission of connecting patients with pre-approval therapies worldwide. By expanding technology, evidence generation, and patient support, the company seeks to remove friction from a historically fragmented process. If executed, the strategy could make earlier access more consistent, more global, and more aligned with how modern therapies are developed.